19 January 2024
19 January 2024
The capital injection will accelerate the development and potential introduction of genetic therapies, including acoramidis.
The regulator issued a complete response letter citing chemistry, manufacturing and controls issues as reasons for its decision.
The proceeds will fund a clinical trial of Comanche’s siRNA therapy in pregnant preeclamptic women that will start later in the year.
Expected to close on 22 January 2024, the German biotech’s offering follows the $1.7bn-topping deal with Moderna struck in late 2023.
Xenetic's deoxyribonuclease (DNase) oncology platform is designed to complement existing cancer treatments.
The approval is based on the positive outcomes of the Phase III ADAPT-SC clinical trial.
In a Phase I/II trial, avutometinib plus sotorasib offered confirmed responses in KRAS G12C inhibitor-resistant patients.
The endocannabinoid inhibitor SYT-510 will be investigated in healthy patients to assess its safety, tolerability, and pharmacokinetics.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials.
Give your business an edge with our leading industry insights.
